NASP Submits Comments on 340B Rebate Model Pilot Program

On April 20, NASP submitted comments to the Health Resources and Services Administration’s (HRSA) urging the administration not to implement a 340B rebate model, arguing it would create severe cash flow burdens for covered entities, disrupt specialty pharmacy operations, and delay or reduce patient access to critical high-cost medications. The letter also raised legal and administrative concerns, recommending instead that HRSA preserve the current upfront discount model and pursue alternative solutions to address program integrity issues. Click here to read the full letter.